Lung Cancer Committee

Purpose

The purpose of the NRG Oncology Lung Cancer Committee is to pursue novel therapeutic strategies toward improving progression-free and overall survival and quality of life for patients with non-metastatic disease.

 

The Committee’s Research priorities include optimizing therapy for patients with both early-stage and locally-advanced lung cancers. Early-stage NSCLC is a heterogeneous patient population, in terms of radiation dose, organs-at-risk, and systemic therapy management. The prognosis for patients with both locally advanced small cell and non-small cell lung cancer is rapidly improving, with the need for further individualized treatment strategies to optimize outcomes based on molecular and anatomical characteristics.

This Committee meets via monthly conference calls and in-person at the NRG Meetings.

 

Lung Cancer Committee Leadership

Chair

Kristin Higgins, MD

Vice Chair

Jessica Donington, MD

Vice Chair

Puneeth Iyengar, MD, PhD

Vice Chair

John Heymach, MD, PhD

Immediate Past Chair

Jeffrey Bradley, MD
Working Groups

Translational Science Lung Cancer Working Group

Chair

Bo Lu, MD, PhD

Core Committee Members
  • Raid Aljumaily
  • Shahed Badiyan
  • Andrew Baschnagel
  • Tammy Bausinger
  • Tithi Biswas
  • Jeff Bradley
  • Stephen Chun
  • James Dignam
  • Jessica Donington
  • Martin Edelman
  • Aaron Franke
  • Carl Michael Gay
  • Daphna Gelblum
  • Michelle Ginsberg
  • Daniel Gomez
  • Vinai Gondi
  • Inga Grills
  • Mark Harkenrider
  • John H. Heinzerling
  • Brian S Henick
  • John Heymach
  • Kristin Higgins
  • Chen Hu
  • Puneeth Iyengar
  • Salma Jabbour
  • Aparna H. Kesarwala
  • Spring Kong
  • Sameera Kumar
  • Vincent Lam
  • Corey Langer
  • Brianna Caroline Lau
  • Ticiana Leal
  • Xing Liao
  • Steven Lin
  • Yufei Liu
  • Bo Lu
  • Neal S. McCall
  • Gregory Masters
  • Martha Matuszak
  • Drew Moghanaki
  • Ben Movsas
  • Abdul Rafeh Naqash
  • Quynh-Nhu Nguyen
  • Nitin Ohri
  • Pradnya D. Patil
  • Rebecca Paulus
  • Bradford A. Perez
  • Jen Petrask
  • Jennifer Presley
  • David Qian
  • Andreas Rimner
  • Clifford Robinson
  • Pam Samson
  • Rafael Santana-Davila
  • Tom Simon
  • Charles Simone
  • Heath Skinner
  • Nancy Soto
  • Alexander Sun
  • Lizbeth A. Swords
  • Sibo Tian
  • Robert Timmerman
  • Theos Tsakiridis
  • Anne Tsao
  • James Urbanic
  • Gregory Videtic
  • Lucus Vitzthum
  • Saiama Waqar
  • Ashley A. Weiner
  • James Welsh
  • Kathryn Winter
General Committee Members
  • Laura Alder
  • Fiori Alite
  • Raid Aljumaily
  • Shahed Badiyan
  • Andrew Baschnagel
  • Tammy Bausinger
  • Eric H. Bernicker
  • Tithi Biswas
  • Edward M. Bleta
  • Jeff Bradley
  • Jason Chan
  • Leslie Chang
  • Nirmal Choradia
  • Stephen Chun
  • Devika Das
  • Jessica Donington
  • Tai Dou
  • Martin Edelman
  • Daffolyn Rachael Fels Elliott
  • Matthew J. Ferris
  • Aaron Franke
  • Carl Michael Gay
  • Daphna Gelblum
  • Oleg Gligich
  • Daniel Gomez
  • Vinai Gondi
  • Ramesh Gopal
  • Mark Harkenrider
  • John Heymach
  • Kristin Higgins
  • Chen Hu
  • Puneeth Iyengar
  • Salma Jabbour
  • Paul Koffer
  • Spring Kong
  • Sameera Kumar
  • Vincent Lam
  • Corey Langer
  • Brianna Caroline Lau
  • Ticiana Leal
  • Xing Liao
  • Steven Lin
  • Bo Lu
  • Gregory Masters
  • Inga Grills
  • Joseph A. Miccio
  • Ben Movsas
  • Quynh-Nhu Nguyen
  • Nitin Ohri
  • Cameron J. Oswalt
  • Pradnya D. Patil
  • Rebecca Paulus
  • Jen Petrask
  • Phillip Pifer
  • Jennifer Presley
  • Krishna Reddy
  • Andreas Rimner
  • Clifford Robinson
  • Carlos A. Rodriguez-Russo
  • Pam Samson
  • Rafael Santana-Davila
  • Austin J. Sim
  • Tom Simon
  • Charles Simone
  • Heath Skinner
  • Nancy Soto
  • Janakiraman Subramanian
  • Alexander Sun
  • Lizbeth A. Swords
  • Robert Timmerman
  • Theos Tsakiridis
  • Anne Tsao
  • James Urbanic
  • Gregory Videtic
  • Lucus Vitzthum
  • Saiama Waqar
  • James Welsh
  • Kathryn Winter
  • Nathan Y. Yu
  • YuanYuan  Zhang
Reset all column filters
Study Title Status Phase Disease Category Disease Site
NRG-LU001

Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC

 Complete II Lung [LU] Non-small Cell Lung Cancer
NRG-LU002

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

 Closed to Accrual II/III Lung [LU] Non-small Cell Lung Cancer
NRG-LU003

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

 Closed to Accrual II Lung [LU] Non-small Cell Lung Cancer
NRG-LU004

Phase I Trial of Radiotherapy Combined with Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

 Complete I Lung [LU] Non-small Cell Lung Cancer
NRG-LU005

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

 Closed to Accrual & Treatment III Lung [LU] Small Cell
NRG-LU006

Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy with or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)

 Closed to Accrual III Lung [LU] Mesothelioma
NRG-LU007

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

 Open to Accrual II/III Lung [LU] Small Cell
NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

 Open to Accrual III Lung [LU] Non-small Cell Lung Cancer
NRGF-001

Activity Monitoring To Improve Patient Care During Chemoradiotherapy For Locally Advanced Non-small Cell Lung Cancer (La-nsclc)

 Terminated I Lung [LU] Non-small Cell Lung Cancer
RTOG-0617

A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

 Terminated III Lung [LU] Non-small Cell Lung Cancer
RTOG-0618

A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer

 Terminated II Lung [LU] Non-small Cell Lung Cancer
RTOG-0813

Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients

 Terminated I/II Lung [LU] Non-small Cell Lung Cancer
RTOG-0839

Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer

 Terminated II Lung [LU] Non-small Cell Lung Cancer
RTOG-0915

A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer

 Terminated II Lung [LU] Non-small Cell Lung Cancer
RTOG-1106

Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

 Terminated II Lung [LU] Non-small Cell Lung Cancer
RTOG-1306

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

 Terminated II Lung [LU] Non-small Cell Lung Cancer
RTOG-1308

Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

 Closed to Accrual III Lung [LU] Non-small Cell Lung Cancer
S1914

SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

 Closed to Accrual III Lung [LU] Non-small Cell Lung Cancer

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.